financetom
Business
financetom
/
Business
/
Update: AMD Q1 Non-GAAP Earnings, Sales Narrowly Beat Expectations; Q2 Revenue Outlook in Line; Shares Fall Premarket
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: AMD Q1 Non-GAAP Earnings, Sales Narrowly Beat Expectations; Q2 Revenue Outlook in Line; Shares Fall Premarket
May 1, 2024 2:17 AM

04:46 AM EDT, 05/01/2024 (MT Newswires) -- (Updates with the stock move in the headline and the first paragraph.)

AMD (AMD) shares fell nearly 7% pre-bell Wednesday after the company reported a narrow beat on adjusted earnings and sales in Q1.

The company reported Q1 non-GAAP earnings late Tuesday of $0.62 per diluted share, up from $0.60 a year earlier.

Analysts surveyed by Capital IQ expected $0.61.

Revenue in the quarter ended March 30 rose to $5.47 billion from $5.35 billion a year earlier.

Analysts surveyed by Capital IQ expected $5.45 billion.

The company expects Q2 revenue of $5.7 billion, plus or minus $300 million. Analysts surveyed by Capital IQ project $5.69 billion.

Price: 147.39, Change: -10.99, Percent Change: -6.94

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
ImmunityBio Says Anktiva Therapy Prolonged Overall Survival in Phase 2 Non-Small Cell Lung Cancer Study
ImmunityBio Says Anktiva Therapy Prolonged Overall Survival in Phase 2 Non-Small Cell Lung Cancer Study
Sep 8, 2025
09:27 AM EDT, 09/08/2025 (MT Newswires) -- ImmunityBio ( IBRX ) said Monday that results from its phase 2 study showed Anktiva therapy reverses lymphopenia and prolongs overall survival in patients with advanced non-small cell lung cancer. Lymphopenia is an adverse effect associated with chemotherapy, radiotherapy, and immunotherapy, and it lowers overall survival rates in various types of cancer, the...
DoorDash Launches All-Night Delivery Service for Waffle House
DoorDash Launches All-Night Delivery Service for Waffle House
Sep 8, 2025
09:25 AM EDT, 09/08/2025 (MT Newswires) -- DoorDash ( DASH ) said Monday it launched an all-night delivery service for restaurant chain Waffle House through its Drive On-Demand service. A number of Waffle House locations in cities such as Atlanta, Charleston, Cincinnati, Columbus, Nashville, and New Orleans are now available for 24/7 delivery on the DoorDash ( DASH ) app,...
Rapport Reports Promising Epilepsy Study Outcomes, Plans Phase 3 Trials Next Year
Rapport Reports Promising Epilepsy Study Outcomes, Plans Phase 3 Trials Next Year
Sep 8, 2025
Rapport Therapeutics, Inc. ( RAPP ) stock traded higher on Monday, with a session volume of 3.20 million compared to the average volume of 179.3 thousand, according to data from Benzinga Pro. On Monday, the company revealed data from the Phase 2a trial of RAP-219 (RAP-219-FOS-201) in patients with drug-resistant focal onset seizures. The study met its primary endpoint, demonstrating...
DuPont secures 10-year US import ban on China's Dawnsens in Tyvek case
DuPont secures 10-year US import ban on China's Dawnsens in Tyvek case
Sep 8, 2025
Sept 8 (Reuters) - DuPont ( DD ) said on Monday China's Dawnsens New-Materials will not sell or import products tied to the chemical company's Tyvek brand in the U.S. for 10 years, as part of a trade secrets dispute resolution. The International Trade Commission approved Dawnsens', also known as Dangs, voluntary agreement to the consent order. The ban, effective...
Copyright 2023-2026 - www.financetom.com All Rights Reserved